SciELO - Scientific Electronic Library Online

 
vol.28Here and now: Lived experiences of professional nurses practising caring presence in a rural public hospital in the North West Province, South AfricaExperiences and mentoring needs of novice nurse educators at a public nursing college in the Eastern Cape author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • On index processCited by Google
  • On index processSimilars in Google

Share


Health SA Gesondheid (Online)

On-line version ISSN 2071-9736
Print version ISSN 1025-9848

Abstract

SHOKANE, Lucky L.; BEZUIDENHOUT, Selente  and  LUNDIE, Maryke. Use of granulocyte colony-stimulating factor in patients with chemotherapy-induced neutropaenia. Health SA Gesondheid (Online) [online]. 2023, vol.28, pp.1-6. ISSN 2071-9736.  http://dx.doi.org/10.4102/hsag.v28i0.2221.

BACKGROUND: Febrile neutropaenia (FN) and resultant infections are the major cause of treatment-related morbidity and mortality in patients receiving chemotherapy. Clinical practice guidelines recommend the use of granulocyte colony-stimulating factors (G-CSF) to reduce the risk of FN and ensuing complications in patients receiving chemotherapy. Despite these recommendations, inappropriate usage of G-CSF has been reported. AIM: To assess prescribing patterns and adherence to international guidelines of G-CSF in adult patients with chemotherapy-induced neutropaenia (CIN) at the haematology oncology wards of the Dr George Mukhari Academic Hospital (DGMAH) and compliance to guidelines. METHODS: Medical records of adult patients who received G-CSF were reviewed retrospectively between 01 January 2018 and 31 July 2018 RESULTS: Of the 128 patient files screened, 57 cases met the inclusion criteria. Duration of treatment with G-CSF was not in accordance with guidelines in more than 50% of the patients and in 43.86%, G-CSF dosing deviated from recommended guidelines. CONCLUSION: The study demonstrated over-prescribing of G-CSF due to either increased doses or duration of G-CSF therapy. Although prescribed for the correct indication, the dosage was often too high or the duration was too long, even once an acceptable neutrophil nadir count was reached. Interventions to optimise the use of G-CSF are required and the pharmacist may play a role in this regard. CONTRIBUTION: The administration of the correct doses of G-CSF can reduce both the severity and duration of neutropaenia. Over-prescribing and incorrect dosing may contribute to patient morbidity and add to the financial burden of healthcare.

Keywords : chemotherapy; febrile neutropaenia; G-CSF; guidelines compliance; dosage.

        · text in English     · English ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License